Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2019-03-31
Target enrollment:
Participant gender:
Summary
Part 1 of the study will determine the maximum tolerated dose (MTD) of EC-18 in subjects with
relapsing or advanced breast cancer whose risk level for febrile neutropenia is low and who
are receiving second line or higher chemotherapy that incorporates
doxorubicin/cyclophosphamide.
Part 2 will evaluate the MTD in the same subject population.